NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis $0.83 -0.01 (-1.19%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.80▼$0.8350-Day Range$0.80▼$0.9452-Week Range$0.74▼$1.76Volume30,503 shsAverage Volume409,989 shsMarket Capitalization$34.06 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Achilles Therapeutics alerts: Email Address Achilles Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside382.6% Upside$4.00 Price TargetShort InterestHealthy0.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.26) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector531st out of 936 stocksBiological Products, Except Diagnostic Industry80th out of 154 stocks 3.0 Analyst's Opinion Consensus RatingAchilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAchilles Therapeutics has received no research coverage in the past 90 days.Read more about Achilles Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.03% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently decreased by 9.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchilles Therapeutics does not currently pay a dividend.Dividend GrowthAchilles Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHL. Previous Next 3.0 News and Social Media Coverage News SentimentAchilles Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Achilles Therapeutics is held by insiders.Percentage Held by Institutions56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Achilles Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Achilles Therapeutics are expected to decrease in the coming year, from ($1.26) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achilles Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achilles Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchilles Therapeutics has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Achilles Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Achilles Therapeutics Stock (NASDAQ:ACHL)Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Read More ACHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACHL Stock News HeadlinesJuly 27 at 1:42 AM | americanbankingnews.comCritical Contrast: Achilles Therapeutics (NASDAQ:ACHL) versus X4 Pharmaceuticals (NASDAQ:XFOR)May 22, 2024 | globenewswire.comAchilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer VaccinesJuly 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 17, 2024 | globenewswire.comAchilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMay 8, 2024 | investorplace.comACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024May 8, 2024 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | globenewswire.comAchilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 17, 2024 | msn.comAchilles Therapeutics plc - Depositary Receipt () (ACHL) Price Target Decreased by 56.41% to 2.89July 27, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.April 5, 2024 | msn.comPiper downgrades Achilles to neutral, cites latest dataApril 4, 2024 | markets.businessinsider.comACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023April 4, 2024 | finanznachrichten.deAchilles Therapeutics PLC: Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsApril 4, 2024 | globenewswire.comAchilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsApril 4, 2024 | globenewswire.comAchilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host ConditioningMarch 7, 2024 | finance.yahoo.comWill Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?February 22, 2024 | wsj.comAchilles Therapeutics PLC ADRFebruary 22, 2024 | benzinga.comAchilles Therapeutics Stock (NASDAQ:ACHL), Short Interest ReportFebruary 9, 2024 | investing.comAchilles Therapeutics PLC ADR (ACHL)See More Headlines Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACHL CUSIPN/A CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+382.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.95% Return on Assets-37.88% Debt Debt-to-Equity RatioN/A Current Ratio9.63 Quick Ratio9.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.24Miscellaneous Outstanding Shares41,088,000Free Float38,877,000Market Cap$34.06 million OptionableNot Optionable Beta1.32 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Iraj Ali Ph.D. (Age 49)CEO & Director Comp: $1.7MDr. Karl Stuart Peggs M.D. (Age 57)Founder & Chief Medical Officer Dr. Sergio A. Quezada Ph.D. (Age 49)Founder & Chief Scientific Officer Mr. Robert Coutts (Age 40)Chief Financial Officer Dr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Founder Dr. Charles Swanton FMEDSCI (Age 51)M.D., Ph.D., Founder Mr. Lee M. SternVice President of Investor Relations & External CommunicationsMr. Daniel Carey Cazel HoodGeneral Counsel & Company SecretaryJulia WilsonHead of CommunicationsMr. Tariq AhmedExecutive Vice President of PeopleMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEAthira PharmaNASDAQ:ATHAAtyr PHARMANASDAQ:ATYRTevogen BioNASDAQ:TVGNOptheaNASDAQ:OPTView All CompetitorsInstitutional OwnershipVirtu Financial LLCSold 18,646 shares on 5/20/2024Ownership: 0.051%Ikarian Capital LLCBought 1,443,181 shares on 5/17/2024Ownership: 3.619%Artal Group S.A.Sold 1,500,000 shares on 5/17/2024Ownership: 1.894%Baker BROS. Advisors LPSold 894,017 shares on 5/15/2024Ownership: 3.031%StemPoint Capital LPBought 1,385,750 shares on 5/14/2024Ownership: 3.475%View All Institutional Transactions ACHL Stock Analysis - Frequently Asked Questions How have ACHL shares performed this year? Achilles Therapeutics' stock was trading at $0.8890 at the beginning of the year. Since then, ACHL stock has decreased by 6.8% and is now trading at $0.8289. View the best growth stocks for 2024 here. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.16. When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO. How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACHL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
